लंदन से पढ़ाई-किसानों की लड़ाई… चौधरी चरण सिंह की विरासत बढ़ाने में जुटे जयंत

You don’t have permission to access “http://www.aajtak.in/elections/up-assembly-elections/story/jayant-singh-rld-profile-political-history-kisan-andolan-western-up-ajit-singh-ntc-1402393-2022-01-31?” on this server. Reference #18.acb52d17.1643601861.aab3a87Continue Reading

जयपुर ने पटना को दी करारी मात, थलाइवाज ने बुल्स को किया चित

You don’t have permission to access “http://www.aajtak.in/sports/news/story/pro-kabaddi-league-pink-panthers-beat-patna-pirates-tamil-thalaivas-edge-past-bengaluru-bulls-tspo-1402434-2022-01-31?” on this server. Reference #18.acb52d17.1643601867.aab49b3Continue Reading

Ministry of Personnel, Public Grievances & Pensions Mentally retarded child entitled to Family Pension: Dr Jitendra Singh Posted On: 30 JAN 2022 7:57PM by PIB Delhi Union Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh…Continue Reading

Ministry of Railways Apprentices trained in railway establishments are given preference in appointment over others, subject to obtaining minimum qualifying marks and meeting and medical standards Demand of apprentices for appointment in railways without undergoing due recruitment process is not acceptable, says RailwayDemand violates constitutional provisions and Apex Court judgment in matters of public employment…Continue Reading

EloQ Communications announced Agency of the Year 2021 by Ad World Masters

Ho Chi Minh, Vietnam, January 30, 2022 –(PR.com)– Vietnam-based public relations and marketing agency EloQ Communications won the Gold title in Ad World Masters’ Agency of the Year 2021 Awards, a unique digital competition that ranks participants based on big data technology. This award marks another achievement in 2021 for EloQ, after receiving “Best PR Agency”…Continue Reading

Belair Produce Enhances Technology with Transition to Produce Pro Software

Woodridge, IL, January 30, 2022 –(PR.com)– Family owned and operated since 1910, Belair Produce understands their success depends upon the loyalty of their customers. This commitment has been the bedrock of their business for over 100 years. With increased demands throughout the industry, especially during the pandemic, Belair Produce knew they had to embrace new technology…Continue Reading

The UK’s Future Role in Military SDA Provision Presented at the Military Space Situational Awareness Conference 2022

London, United Kingdom, January 30, 2022 –(PR.com)– Space debris is a global problem and the joint initiative announced earlier this year from the UK Space Agency’s National Space Technology Programme (NSTP) and Space, Surveillance and Tracking Programme (SST) will enable UK companies to mature technologies and early phase concepts to help tackle the issue including old…Continue Reading

LoyaltyXpert Announces New Customer Services as Voucher Redemption in their Loyalty Program Solution

Ahmedabad, India, January 30, 2022 –(PR.com)– LoyaltyXpert, one of the best loyalty program solution providers in India, has announced the introduction of new customer services as voucher redemption in their loyalty program solution.Under the new service, customers will get an option to redeem their points by purchasing existing vouchers from a wide range of categories and…Continue Reading

Cisdem AppCrypt 6.6.0 Adds the Ability to Redirect Blocked Websites to Custom URL

Chicago, IL, January 30, 2022 –(PR.com)– Cisdem AppCrypt for Mac can block websites and lock apps with password. It allows users to block access to specific websites and webpages on web browsers. It can also password protect apps on Mac.“AppCrypt 6.6.0 comes with a new feature,” said Edward Riley, Cisdem’s project manager. “AppCrypt allows users to…Continue Reading

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

TOKYO, Jan 31, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA (generic name: pembrolizumab) has been approved in Taiwan for the first-line treatment of patients with advanced…Continue Reading